Long-Term Safety of MorphiDex®

Slides:

Advertisements

Similar presentations

Treatment of postherpetic neuralgia: a review of therapeutic options Charles E. Argoff, MD, Nathaniel Katz, MD, Miroslav Backonja, MD Journal of Pain and.

Advertisements

Comparison of the Constipation Assessment Scale and Plain Abdominal Radiography in the Assessment of Constipation in Advanced Cancer Patients Kittiphon.

Impact of a Clinical Pharmacist-Led Guidance Team on Cancer Pain Therapy in China: A Prospective Multicenter Cohort Study Jian Chen, PhD, Xiao-yang Lu,

Oropharyngeal Mucositis Pain Treatment with Transdermal Buprenorphine in Patients After Allogeneic Stem Cell Transplantation Samuel Vokurka, MD, PhD

The use of ondansetron for nausea and vomiting after head injury and its effect on return rates from the pediatric ED Jesse J. Sturm, MD, MPH, Harold.

Winston C. -V. Parris, MD, Benjamin W. Johnson, MD, Marilyn K

Wen Jing Chung, MD, MS, Gregory H. Pharo, DO

Susan Enguidanos, PhD, MPH, Jennifer Ailshire, PhD

An Assessment of the Safety, Eff icacy, and Acceptability of Intranasal Fentanyl Citrate in the Management of Cancer-Related Breakthrough Pain Giovambattista.

Effects of High Dose Opioids and Sedatives on Survival in Terminally Ill Cancer Patients Tatsuya Morita, MD, Junichi Tsunoda, MD, Satoshi Inoue, MD,

Impact of a Clinical Pharmacist-Led Guidance Team on Cancer Pain Therapy in China: A Prospective Multicenter Cohort Study Jian Chen, PhD, Xiao-yang Lu,

Comparison of Tropisetron and Chlorpromazine Combinations in the Control of Nausea and Vomiting in Patients with Advanced Cancer Kyriaki Mystakidou,

Anita L Comley, PhD, RN, AOCN, Elaine DeMeyer, RN, MSN, AOCN

Patient-Controlled Analgesia With Intravenous L-Methadone in a Child With Cancer Pain Refractory to High-Dose Morphine Rainer Sabatowski, MD, Stefan.

Rapid Progression of Advanced “Hormone-Resistant” Prostate Cancer During Palliative Treatment with Progestins for Cancer Cachexia Davide Tassinari, MD,

Midazolam as Adjunct Therapy to Morphine in the Alleviation of Severe Dyspnea Perception in Patients with Advanced Cancer Alfredo H. Navigante, MD, PhD,

Oropharyngeal Mucositis Pain Treatment with Transdermal Buprenorphine in Patients After Allogeneic Stem Cell Transplantation Samuel Vokurka, MD, PhD

Acupressure Bands Are Effective in Reducing Radiation Therapy-Related Nausea Joseph A. Roscoe, PhD, Peter Bushunow, MD, Pascal Jean-Pierre, PhD, Charles.

Coxibs—Beyond the GI Tract

Bowel dysfunction after laparoscopic antireflux surgery: incidence, severity, and clinical course Alexander Klaus, MD, Ronald A Hinder, MD, PhD, Kenneth.

Self-Reported Constipation in Patients With Advanced Cancer: A Preliminary Report Wadih Rhondali, MD, Linh Nguyen, MD, Lynn Palmer, PhD, Duck-Hee Kang,

Safety and Effectiveness of Palliative Drug Treatment in the Last Days of Life—A Systematic Literature Review Kristian Jansen, MD, Dagny F. Haugen, MD,

Delirium in Terminal Cancer

The Direct and Indirect Costs of Opioid-Induced Constipation

Renée A. Harrison, PhD, Seng-jaw Soong, PhD, Heidi L

Complementary and Alternative Medicine in the Management of Pain, Dyspnea, and Nausea and Vomiting Near the End of Life Cynthia X. Pan, MD, R.Sean Morrison,

Isaac M. Bromberg, MD Journal of Pain and Symptom Management

Morphine with Dextromethorphan

Gastrointestinal Effects of NSAIDs and Coxibs

Family Caregiver Perspectives on Symptoms and Treatments for Patients Dying From Complications of Cystic Fibrosis Elisabeth P. Dellon, MD, MPH, Mitchell.

Transdermal Fentanyl for Chronic Pain in AIDS

Long-term safety of cilostazol in patients with peripheral artery disease: The CASTLE study (Cilostazol: A Study in Long-term Effects) William R. Hiatt,

Age-Associated Differences in Fatigue Among Patients with Cancer

Redefining Appropriate Treatment Expectations

Kerala, India Journal of Pain and Symptom Management

Insight Into Advance Care Planning for Patients on Dialysis

Jodi L. Hannan, MD, Steven M. Radwany, MD, Terry Albanese, PhD

Cancer patients' share in a population's Use of opioids

The Role of Patients' Expectations in the Development of Anticipatory Nausea Related to Chemotherapy for Cancer Jane T. Hickok, MD, MPH, Joseph A. Roscoe,

Amitriptyline in the Treatment of Chemotherapy-Induced Neuropathic Symptoms Anna-Liisa Kautio, MD, Maija Haanpää, MD, PhD, Tiina Saarto, MD, PhD, Eija.

Barrie R. Cassileth, PhD, Andrew J. Vickers, PhD

Efficacy and Side Effects of Diclofenac Patch in Treatment of Patients with Myofascial Pain Syndrome of the Upper Trapezius Lin-Fen Hsieh, MD, Chang-Zern.

Steven Z. Pantilat, MD, Kathleen M. Kerr, BA, J

Robert L. Jayes, MD, Robert M. Arnold, MD, Erik K. Fromme, MD

Prevalence and Characteristics of Breakthrough Pain in Cancer Patients Admitted to a Hospice Giovambattista Zeppetella, BSc (Hons), MRCGP, Catherine.

Health-Related Quality of Life in Chronic Refractory Reflex Sympathetic Dystrophy (Complex Regional Pain Syndrome Type I) Marius A Kemler, MD, Henrica.

Methadone Analgesia in Cancer Pain Patients on Chronic Methadone Maintenance Therapy Paolo L Manfredi, MD, Gilbert R Gonzales, Andrea L Cheville, Craig.

Patients' Hopes for Advanced Cancer Treatment

The Assessment of Cancer Pain in North India

Which Treatment Is Better

Gertrud Andersen, MD, Lona Christrup, PhD, Per Sjøgren, MD

Is the B12/CRP Index More Accurate Than You at Predicting Life Expectancy in Advanced Cancer Patients? Filipa Tavares, MD Journal of Pain and Symptom.

Longitudinal Quality of Life in Advanced Cancer Patients

Evaluating the Quality of Dying and Death

Palliative Care Consultations

Hospice Care for Heart Failure Patients

A Scale for Measuring Patient Perceptions of the Quality of End-of-Life Care and Satisfaction with Treatment Daniel P. Sulmasy, OFM, MD, PhD, Jessica.

A Meta-Analysis of the Relationship Between Response Expectancies and Cancer Treatment-Related Side Effects Stephanie J. Sohl, PhD, Julie B. Schnur,

A Preliminary Study of the Utility of the Brief Hospice Inventory

The Asia Pacific Hospice Palliative Care Network

Similarity and Difference Among Standard Medical Care, Palliative Sedation Therapy, and Euthanasia Tatsuya Morita, MD, Kei Hirai, PhD, Tatsuo Akechi,

Physical Function in Patients with Cancer

Nathaniel P Katz, MD Journal of Pain and Symptom Management

Tofacitinib therapy for children with severe alopecia areata

Using the Symptom Monitor in a Randomized Controlled Trial: The Effect on Symptom Prevalence and Severity Johanna Hoekstra, MA, Rien de Vos, PhD, Nico.

Gerd Inger Ringdal, PhD, Marit S Jordhøy, MD, Stein Kaasa, PhD

A pilot study of equal doses of 10% IGIV given intravenously or subcutaneously Shilpa H. Desai, BS, MD, Akhil Chouksey, MD, John Poll, RN, Melvin Berger,

Longitudinal Documentation of Cancer Pain Management Outcomes

Scrambler Therapy May Relieve Chronic Neuropathic Pain More Effectively Than Guideline-Based Drug Management: Results of a Pilot, Randomized, Controlled.

Nausea and Vomiting Remain a Significant Clinical Problem

Presentation transcript:

Long-Term Safety of MorphiDex® Ronald Goldblum, MD Journal of Pain and Symptom Management Volume 19, Issue 1, Pages 50-56 (January 2000) DOI: 10.1016/S0885-3924(99)00131-1

Fig. 1 The MorphiDex® exposure population shows a decreasing percentage of somnolence during 12 months of treatment Journal of Pain and Symptom Management 2000 19, 50-56DOI: (10.1016/S0885-3924(99)00131-1)

Fig. 2 The prevalence rate of somnolence in the MorphiDex® exposure population (open bars) as compared to the population completing 9 months of MorphiDex® therapy (N = 278) (shaded bars) shows the change over time is due to the decrease in the incidence of somnolence, and not related to subject discontinuation during MorphiDex® therapy Journal of Pain and Symptom Management 2000 19, 50-56DOI: (10.1016/S0885-3924(99)00131-1)

Fig. 3 The prevalence rate of nausea in the MorphiDex® exposure population (open bars) as compared to the population completing 9 months of MorphiDex® therapy (shaded bars) also shows a decrease in the incidence of nausea over time Journal of Pain and Symptom Management 2000 19, 50-56DOI: (10.1016/S0885-3924(99)00131-1)

Fig. 4 The prevalence rate of constipation in the MorphiDex® exposure population (open bars) as compared to the population completing 9 months of MorphiDex® therapy (shaded bars) shows, after an initial slight decrease, the incidence of constipation is fairly constant over time Journal of Pain and Symptom Management 2000 19, 50-56DOI: (10.1016/S0885-3924(99)00131-1)

Fig. 5 The prevalence rate of dizziness in the MorphiDex® exposure population (open bars) as compared to the population completing 9 months of MorphiDex® therapy (shaded bars) shows dizziness also decreases over time Journal of Pain and Symptom Management 2000 19, 50-56DOI: (10.1016/S0885-3924(99)00131-1)

Fig. 6 The prevalence rate of confusion in the MorphiDex® exposure population (open bars) as compared to the population completing 9 months of MorphiDex® therapy (shaded bars) shows confusion decreases over time Journal of Pain and Symptom Management 2000 19, 50-56DOI: (10.1016/S0885-3924(99)00131-1)

Fig. 7 The prevalence rate of vomiting in the MorphiDex® exposure population (open bars) as compared to the population completing 9 months of MorphiDex® therapy (shaded bars) shows the number of patients reporting vomiting declines after 3 months of therapy Journal of Pain and Symptom Management 2000 19, 50-56DOI: (10.1016/S0885-3924(99)00131-1)